Multivariate analysis in METABRIC cohort observed that UBE2C expression was an independent prognostic marker significantly associated with poor patient outcome in terms of BCSS (p < 0.001, HR 1.90, 95% CI; 1.50–2.38), regardless of LVI, tumour size, ER and HER2 status (Table 3). Here, UBE2C is linked to neoplasm.